Jon Farley

Jon Farley, PhD, is a Senior Scientist at Alnylam Pharmaceuticals specializing in CNS Target Biology since December 2019. Prior to this, Jon worked as a Postdoctoral Research Fellow at Sanofi Genzyme from January 2018 to November 2019, focusing on drug discovery and remyelination therapeutics for Multiple Sclerosis. Jon's early research experience includes a Graduate Student role at the University of Massachusetts Medical School from September 2012 to December 2017, where Jon identified genes related to Wallerian degeneration and studied the role of the transcription factor Pebbled/RREB1. Jon's career began at Massachusetts General Hospital from November 2007 to August 2012 as a Research Technician, where Jon investigated TorsinA's function and Parkinson’s Disease-related deficiencies. Jon earned a Ph.D. in Neuroscience from UMass Chan Medical School and a B.A. in Biochemistry and Molecular Biology from Boston University.